- Home
- SGRY vs IBRX Comparison
SGRY vs IBRX Comparison
Compare SGRY & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGRY
- IBRX
- Stock Information
- Founded
- SGRY 2004
- IBRX 2014
- Country
- SGRY United States
- IBRX United States
- Employees
- SGRY N/A
- IBRX N/A
- Industry
- SGRY Hospital/Nursing Management
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGRY Health Care
- IBRX Health Care
- Exchange
- SGRY Nasdaq
- IBRX Nasdaq
- Market Cap
- SGRY 2.7B
- IBRX 2.4B
- IPO Year
- SGRY 2015
- IBRX N/A
- Fundamental
- Price
- SGRY $21.22
- IBRX $2.47
- Analyst Decision
- SGRY Buy
- IBRX Strong Buy
- Analyst Count
- SGRY 8
- IBRX 5
- Target Price
- SGRY $37.57
- IBRX $11.35
- AVG Volume (30 Days)
- SGRY 995.2K
- IBRX 8.0M
- Earning Date
- SGRY 05-06-2025
- IBRX 05-08-2025
- Dividend Yield
- SGRY N/A
- IBRX N/A
- EPS Growth
- SGRY N/A
- IBRX N/A
- EPS
- SGRY N/A
- IBRX N/A
- Revenue
- SGRY $3,114,300,000.00
- IBRX $14,745,000.00
- Revenue This Year
- SGRY $10.91
- IBRX $621.53
- Revenue Next Year
- SGRY $9.15
- IBRX $163.57
- P/E Ratio
- SGRY N/A
- IBRX N/A
- Revenue Growth
- SGRY 13.52
- IBRX 2270.58
- 52 Week Low
- SGRY $19.50
- IBRX $2.28
- 52 Week High
- SGRY $33.97
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- SGRY 35.50
- IBRX 41.67
- Support Level
- SGRY $20.88
- IBRX $2.35
- Resistance Level
- SGRY $21.47
- IBRX $3.04
- Average True Range (ATR)
- SGRY 0.97
- IBRX 0.28
- MACD
- SGRY -0.08
- IBRX -0.02
- Stochastic Oscillator
- SGRY 37.39
- IBRX 13.19
About SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.